Givinostat Slows Duchenne Muscular Dystrophy Decline
Givinostat (Duvyzat) slowed physical decline as measured by stair climbing speed for a subset of boys with Duchenne muscular dystrophy (DMD), according to the phase III trial that supported the drug’s recent approval for this indication. While the boys still declined over 72 weeks on the oral drug, their times for a four-stair climb assessment […]
Novel Drug Approved for All Duchenne Muscular Dystrophy Variants
The FDA approved oral givinostat (Duvyzat) to treat Duchenne muscular dystrophy (DMD) in patients ages 6 years and older, the agency announced Thursday. Givinostat is a histone deacetylase (HDAC) inhibitor that targets pathogenic processes to reduce inflammation and loss of muscle. It’s the first nonsteroidal drug approved for patients with all genetic variants of DMD, […]